I. Conney AH, Pantuck EJ, Hsiao K-C, et al. Enhanced phenacetin metabolism in human subjects fed charcoal-broiled beef. Clin Phannacol 'fher 1976;20:633fi42 2. Crichton M. The Lost World. New York, NY: Ballantine Books; 1996: 189-190 3. Guengerich FP. Cytochrome P450 enz-yenes. American Scientist 1993;81: 44047 4. Nelson DR, Koymans L, Kamataki T, et al. P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharrnacogenetics 1996;6:1-42 S. Musso DL, Mehta NB, Soroko FE, et al. Synthesis and evaluation of the antidepressant activity of the enantiomers of bupropion. Chirality 1993;5: 495-500 6. Stevens JC, W~ghton SA. Interaction of the enantiomers of fluoxetine and norfluoxetine with human liver cytochromes P450. J Pharrnacol Exp Ther 1993;266:964-971 7. Kaminsky LS, Zhang Z-Y Human P450 metabolism of warfarin. Pharmacol Ther 1997;73:67- 8. Chirality [editorialJ. Lancet 1990;336:1 l00-1101 9. Poulsen L, Arendt-Nielsen L, Brgsen K, et al. The hypoalgesic effect of tramadol in relation to CYP2D6. Clin Pharmacol Ther 1996;60:6344 10. Inaba T, Nebert DW, Burchell B, et al. Pharmacogenetics in clinical phar macology and toxicology. Can 1 Physiol Pharmacol 1995;73:331-338 11. Jefferson 1W, Greist JH. Brussels sprouts and psychopharmacology: understanding the cytochrome P450 enryme system. In: Jefferson JW, Greist JH; eds. Psychiatric Clinics of North America: Annual of Drug Therapy. Philadelphia, Pa: Saunders; 1996;3:205-222 12. Edwards DJ, Bellevue FH, Woster PM. Identification of 6',7'-dihydroxybergamottin, a cytochrome P450 inhibitor, in grapefruit juice. Drug Metab Dispos 1996;24:1287-1290 13. Agrawal AK, Shapiro BH. Imprinted overinduction of hepatic CYP2B I and 2B2 in adutt rats neonatally exposed to phenobarbital. J Pharmacol Exp Ther 1996;279:991-999 14. Ring BJ, Catlow J, Lindsay TJ, et al. Identification of the human cytochrome P450 responsible for the in vitro formabon of the major oxidative metabolites of the antipsychotic agent olanzapine. J Pharmacol Exp Ther 1996;276:658-166 l5. Larsen-Su S, Williams DE. Dietary indole-3-carbinol inhibits FMO activity and the expression of flavin-containing monooxygenase form 1 in rat liver and intestine. Drug Metab Dispos 1996;24:927-931 16. Gonzalez FJ, Gelboin HV. Role of human cytochromes P450 in the metabolic activation of chemical carcinogens and toxins. Dmg Metab Rev 1994;26:165-183 17. Guengerich FP Human cytochrome P450 enzymes. In: Ortiz de Montellano PR, ed. Cytcxhrome P450 Structure, Mechanism, and Biochemistry, 2nd ed. New York, NY: Plenum; 1995:473-535 18. Park BK, Pirmohamed M, Kitteringham NR. The role of cytochrome P450 enzymes in hepatic and extrahepatic hutnan drug toxicity. Pharmacol Ther 1995;68:38524 19. Koyama E, Chiba K, Tani M, et al. Identificalion of human cytochrome P450 isofonns involved in the stereoselective metabolism of mianserin enantiomers. J Pharmacol Exp Ther 1996;275:21-30 20. Mimura M, Baba T, Yamazaki H, et al. Characterization of cytochrome P-450 2B6 in human liver microsomes. Drug Metab Dispos 1993:21: 1048-1056 21. Shimada T, Yamazaki II, Mimura M, et al. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs. carcinogens and toxic chemicals; studies with fiver microsumes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994;270:41423 22. Nakajima T, Elovaara E, Gonzalez FJ, et al. Characterization of the hurnan cytochrome P450 isozymes responsible for styrene metabolism. In: Sorsa M, Peltonen K, Vainio H, et al., eds. Butadiene and Styrene: Assessment of Health Hazards. fARC Scientific Publications 1993;127:101-108 23. Chang TKH, Weber GF, Crespi CL, et al. Differential activation uf cyclophosphamide and ifosphamide hy cytochromes P-450 2B and 3A in hunian liver microsomes. Cancer Res 1993;53:5629-5637 24. Baker MT, Olson MJ, Wang Y, et al. Isoflurane-chlorodifluoroethene interaction in hunian liver microsomes: role of cytochrome P4502B6 in potentiation of halothane metabolism. Drvg Metab Dispos 1995;23:60-64 25. Heyn Ii, White RB, Stevens JC. Catalytic role of cytuchrume P450286 in the N-demethylatiun of S-mephenytoin. Dmg Metab Dispos 1996;24: 948-954 26. Ono S, Hatanaka T, Miyazawa S, et al. Hunian liver microsornal diazepam metabolism using cDNA-expressed cytochrome P450s: role of CYP2B6, 2C19 and the 3A subfamily. Xenobiotica 1996;26:1 155-I 166 27. Flammang AM, Gelboin HV, Aoyama T, et al. Nicotine metabolism by cDNA-expressed hunian cytochrome P-450s. Biochemical Archíves 1992; 8: I-8 28. Nakajima M, Yamamoto T, Nunoya K, et al. Role of hunian cytuchrome P4502A6 in c- oxidation of nicotine. Drug Metab Dispos 1996;24: 1212-1217 29. Ketter TA, Jenkins JB, Schrueder DH, et al. Carbamazepine but not valproate induces bupropion metabolism. J Clin Psychophannacol 1995;15: 327-333 30. Reidy GF, Mehta I, Murray M. Inhibition of oxidative drug metabolism by orphenadrine: in vitro and in vivo eviáence for isuzyme-specific complexation of cytochrome P-450 and inhibition kinetics. Mol Pharmacol 1989; 35:736-743 31. Guo Z, Raeissi S, White RB, et al. Orphenadríne and methimazole inhibit tnultiple cytochrome P450 enzymes in hunian liver tnicrosomes. Drug Metab Dispos 1997;25:390-393 32. Goldstein 1, de Morais SMF Biochemistry and molecular biology of the hunian CYP2C subfamily. Phannacogenetics 1994;4:285-299 33. Daniel Hl, Edeki Tl. Genetic polymorphistn of S-mephenytoin 4'-hydroxylation. 34. Flockhart DA. Drug interactions and the cytochrome P450 system. Clin Phannacokinet 35. Kroemer HK, Eichelbaum M. It's in the genes, stupid: molecular bases and clinical consequences of genetic cytochrome P450 2D6 polymorphism [minireview]. Lif'e Sci 1995;56:2285-2298 36. Edeki TI, He H, Wood AJJ. Pharmacogenetic explanation for excessive (i-blockade following timolol eye drops: potential for oral-ophthalmic drog interaction. JAMA 1995;274:16(1-1613 37. Dahl ML, Bertilsson L, Johansson I, et al. Phannacogenetics and isozyme specific drog interactions in psychopham~acology [abstract]. Neuropsychophannacology 1994;10:4885 38. BrOsen K. Are pharmacokinetic drog interactions with the SSRIs an issue? Int Clin 39. Riesenman C. Antidepressant drog interactions and the cytochrome P450 system: a critical appraisal. Psychopharmacology 1995;15:845-99S 40. Price LH, Chamey DS. Delgado PL, et al. Fenfluramine augmentation in depression. 1 Clin Psychopharmacol 1990;10:312-317 41. Carriére V, Berthou F, Baird S. et al. Hunian cytochrome P450 2El (CYP2E1): from genotype to phenotype. Pharn~acogenetics 1996;6: 203-211 42. Valentine JL, Lee S-T, Seaton MJ, et al. Reduction of benzene metabolism and toxicity in mice that lack CYP2E I expression. Toxicol Appl Phannacol 1996;141:205-213 43. Lieber CS. Medical disorders of alcoholism. N Engl J Med 1995;333: 1058-(065 44. Kharasch I?D, f-lankíns D. Maulz D, et al. Identificaticm of thc cnzymc rcsponsible for oxidative halothane metabolism: implications for prevention of halothane hepatitis. Lancet 1996;347:1367-! 371 45. Watkins PB. Noninvasive tests of CYP3A enzymes. Pharmacogenetics 1994;4:171-184 46. Ketter TA, Flockhart DA, Post RM, et al. The emerging role of cytochrome P450 3A in psychopharmacology. J Clin Psychopharmacol 1995;15: 387-398 47. Li AP, Kaminski DL, Rasrnussen A. Substrates of human hepatic cytochrome P450 3A4. 48. Spatzenegger M, Jaeger W. Clinical importance of hepatic cytochrome P450 in drog metabolism. Drog Metab Rev 1995;27:397 l7 49. Deeks SG, Smith M, Holodniy M, et al. HIV-1 protease inhibitora: a review for clinicians. 50. Greenblatt Dl, von Moltke LL, Harmatz JS, et al. Interaction of triazolam and ketoconazole. 51. Neuvonen PJ, Jalava K-M. Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid. Clin Phannacol Ther 1996; 60:54-61 52. Ducharme MP, Slaughter RL, Warbasse LH, et al. Itraconazole and hydroxyitraconazole serem concentrations are reduced more than tenfold by phenytoin. Clin Pharmacol Ther 1995;58:617-624 53. Saklad S. Communication in: Clinical psychopharmacology online. Curr Afflllness 1996;15:19 54. Villikka K, Kivistö KT, Backman JT, et al. Triazolam is ineffective in patients laking rifampin. 55. Ketter TA, Callahan AM, Post RM. Nefazodone relief of alprazolam interdose dysphoria: a potential therapeutic benefit of 3A3/4 inhibition [letter]. J Clin Psychiatry 1996;57:307 56. Keogh A, Spratt P, McCosker C, et al. Ketoconazole to reduce the need for cyclosporine after cardiac transplantation. N Engl J Med 1995;333: 628-633 57. Pollock BG. Recent developments in drog metabolism of relevance to psychiatrists. Harv Rev 58. Baumann P Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitora. Clin Pharmacokinet 1996;31:44469 59. Baumann P, Rochat B. Comparative pharmacokinetics of selective seroto nin reuptake inhibitora: a look behind the mitror. Int Clin Psychopharmacol 1995; IO(suppt 1 ): l5-2l 60. Meyer UA, Amrein R, Balant LP, et al. Antidepressants and dmg-metabolizing enzymes: expert group report. Acta Psychiatr Scand 1996;93:71-79 61. Rosenbaum JF. Drog interactions and the cytochrome P450 system: clini cal implications for selective serotonin reuptake inhibitora. Clin Pharmacokinetic 1995;29(suppl 1):l-61 62. Nemeroff CB, DeVane L, Pollock BG. Newer antidepressants and the cytochrome P450 system. Am J Psychiatry 1996;153:311-320 63. Harvey AT, Preskorn SH. Cytochrome P450 enzymes: interpretation of their interactions with selective serotonin reuptake inhibitora, I. J Clin Psychopharmacol1996;16:273-285 64. Harvey AT, Preskorn SH. Cytochrome P450 enzymes: interpretation of their interactions with selective serotonin reuptake inhibitora, II. J Clin Psychophannacol1996;16:345-355 65. Preskorn SH. Clinically relevant pharn~acology of selective serotonin reuptake inhibitora. Clin 66. Preskom SH. Effects of antidepressants on the cytochrome P450 systems. Am J Psychiatry 67. Nemeroff CB, DeVane CL, Pollock BG. Reply to SH Preskom: effects of antidepressants on the cytochrome P450 system [letter]. Am J Psychiatry 1996;153:1656-1657 68. Preskorn SH. Drog-drog interactions [letter with reply]. J Clin Psychiatry 1996;57:223-225 69. DeVane CL. Reply to Preskom SH: Drog-drog interactions [letter]. J Clin Psychiatry 70. Spigset 0, Carleborg L, Hedenmalm K, et al. Effect of cigarette smoking on tluvoxamine phannacokinetics in humans. Clin Pharmacol Ther 1995; 58:39903 71. Aspeslet LJ, Baker GB, Coutts RT, et al. The effects of desipramine and iprindole on levels of enantiomers of fluoxetine in rat órain and urine. Chirality 1994;6:86-90 72. Sproule BA, Otton V, Cheung SW, et al. CYP2D6 inhibition in patients treated with sertraline. 73. Kobayashi K, Chiba K, Yagi T, et al. Identification of cytochrome P450 isoforms involved in citalopram N-demethylation by hunian liver microsomes. J Pharmacol Exp Ther 1997;280:927-933 74. Jeppesen U, Gram LF, Vistisen K, et al. Dose-dependent inhibition of CYPIA2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine. Eur J Clin Pharmacol 1996;51:73-78 75. Preskom SH, Alderman J, Chung M, et al. Phannacokinetics of desipramine coadministered with sertraline or fluoxetine. J Clin Psychophannacol 1994;14:90-98 76. Lasher TA, Fleishaker JC, Steenwyk RC, et al. Phannacokinetic pharmacodynamic evaluation of the combined administration of alprazolam and fluoxetine. Psychophannacology 1991;104:323-327 77. Shader RI, Greenblatt DJ, von Moltke LL. Fluoxetine inhibition of phenytoin metabolism. J Clin 78. Carrillo JA, Dahl ML, Svensson J-O, et al. Disposition of fluvoxamine in humans is detennined by the polymorphic CYP2D6 and also by the CYPI A2 activity. Clin Pharmacol Ther 1996;60:183-190 79. Rasmussen BB, Muenpü~ J, Pelkonen O, et al. Selective serotonin reuptake inhibitora and theophylline metabolism in hunom liver microsomes: potent inhibition by fluvoxamine. Br J Clin Pharmacol 1995:39:151-159 80. Jeepesen U, Loft S, Poulsen H, et al. A fluvoxamine-caffeine interaction study. 81. Koponen H, Leinonen E, Lepola U. Fluvoxamine increases the clozapine serem levels significantly. Eur Neuropsychopharmacol 1996;6:69-71 82. von Moltke L, Greenblatt D, Duan SX, et al. Inhibition of terfenadine metabolism in vitro by azole antifungal agents and by selective serotonin reuptake inhibitor antidepressants: relation to pharmacokinetic interactions in vivo. J Clin Psychophannacol 1996;16:104-112 83. Aldennan J, Allison J, Chung M, et al. Desipramine with paroxetine or sertraline. In: New Research Program and Abstracts of the 147th Annual Meeting of the American Psychiatric Association; May 26. 1994; Philadelphia, Pa. Abstract NR610:215 84. Hamelin BA, Turgeon J, Vallée F, et al. The disposition of fluoxetine bot not sertraline is altered in poor metabolizers of debrisoquine. Clin Pharmacol Ther 196;60:512-521 85. Catterson ML, Preskom SH. Phannacokinetics of selective serotonin reuptake inhibitora: clinical relevance. Pharmacol Toxicol 1996;78:203-208 86. Ring BJ, Binkley SN, Roskos L, et at. Effect of fluoxetine, norfluoxetine, sertraline and desmethyl sertraline on human CYP3A catalyzed I'-hydroxy midazolam fonnation in vitro. J Phannacol Exp Ther 1995;275: 1131-1135 87. Haselberger MB, Freedman LS, Tolbert S. Elevated serem phenytoin concentrations associated with coadministration of sertraline. J Clin Psychopham~acol 1997;17:107-109 88. Otton SV, Ball SE, Cheung SW, et al. Venlafaxine oxidation in vitro is catalysed by CYP2D6. 89. Ball S, Ahern D, Kao J, et al. Venlafaxine (VF): effects on CYP2D6 dependent imipramine (IMP) and desipramine (DMP) 2-hydroxylation: comparative studies with fluoxetine (FLU) and effects on CYPIA2, CYP3A4 and CYP2C9. Clin Pharmacol Ther 1996;59:170 90. Hodgman MJ, Marlin TG, Krenzelok EE Serotonin syndrome due to venlafaxine and maintenance tranylcypromine therapy. Hum Exp Toxicol 1997:16:14-17 9l. Ellingrod VL, Perry PJ. Nefazodone: a new antidepressant. Am J Iiealth Syst Pham~ 92. l3arbhaiya RH, Buch AB, Greene DS. Single and multiple dose pharmacokinetics of nefazodone in subjects classified as extensive and poor metabolizers of dextromethorphan. Br J Clin Pharmacol 1996;42: 573-581 93. Preskorn SH, Magnus RD, Horst D, et al. Phamiacokinetic and phannacodynamic effects of co- administration of nefazodone and desipramine to nonnal volunteers. In: New Research Program and Abstracts of the 149th Annual Meeting of the American Psychiatric Association; May 7, 1996; New York, NY. Abstract NR 195:120 94. Greene DS, Salazar DE, Dockens RC, et al. Coadministration of nefazodone and benzodiazepines, IV. A phannacokinetic interaction study with lorazepam. J Clin Psychopharmacol 1995;15:409-416 95. f'ollock BG, Sweet RA, Kirslmer M, et al. Bupropion plasrna levels and CYp2D6 phenotype. 96. I'reskorn SH. Should bupropion dosage be adjusted based upon therapeutic drog monitoring? 97i. ;ihad MU, Preskom SH. A possible bupropion and imipramine interaction. J Clin 98. Verhoeven CHJ, Vos RME, Bogaards JJP. Characterization and inhibition of hunian cytochrome P-450 enzymes involved in the in vitro metabolism of mirtazapine [abstract]. Eur Neuropsychophannacol 1996:6(suppl 4):63 99. Dahl M-L, Voortman G, Alm C, et al. In vitro and in vivo studies on the disposition of mirtazapine in humans. Clinical Drug Investígations J Clin Psychiatry 1998;59 (suppl 4)1997;13:376 100. Sternback H. The serotonin syndrome. Am J Psychiatry 1991;148: 705-713 101. Lejoyeux M, Adés J, Rouillon F. Serotonin syndrome: incidence, symptoms and treatment. 102. Bodner RA, Lynch T, Lewis L, et al. Serotonin syndrome. Neurology 1995;45:219-223 103. Mills KC. Serotonin syndrome. Am Fam Physician 1995;52:1475-1482 104. Hoes M1, Zeijpveld 1H. Mirtazapine as treatment for serotonin syndrome [letterj. 105. Pedrinola F, Sztejnsznajd C, Lima N, et al. The addition of dexfenfluramine to fluoxetine in the treatment of obesity: a randomized clinical trial. Obes Res 1996;4:549-554 106. Steinmuller W. Communication in: Clinical psychopharmacology online. 107. Physicians' Desk Reference. Montvale, NJ: Medical Economics; 1997


Ecs congenital cardiac abnormalities (learner).indd

Congenital Cardiac Abnormalities S i m u l a t e d C l i n i c a l E x p e r i e n c e ( S C E ™ ) O v e r v i e w L e a r n i n g O b j e c t i v e s Location: General Pediatrics Unit 1. Uses history and assessment fi ndings to plan, prioritize, and provide developmentally appropriate care to the infant patient with Down History/Information: syndrome (trisomy 21) and congeni

Teoksen ensimmäinen painos ilmestyi Hämeenlinnassa Arvi A. Karisto Osakeyhtiön julkaisemana vuonna 1927. SyväysEero KaskiUlkoasu: Risto PenttinenKustantaja: Pilot-kustannus Oy 2008ISBN 978-952-464-782-3Print-on-demandMontakaan askelta en ehtinyt puistokäytävällä, kun jostakin sivummalta, pensaitten keskeltä, ka-jahti kova ja kimakka laukaus läpi selkeän syysil-man. En sanottavasti

Copyright © 2010-2014 Medical Articles